Home | About eMedicine | Contact Us
  

Christopher P. Cannon, MD
Welcome and Program Introduction (4:55)
Christie M. Ballantyne, MD
The Rampancy of Cardiovascular Disease: Can It Be Blocked? (13:17)
Jean-Pierre Després, PhD
The Endocannabinoid System: The Physiologic Mechanisms Behind Metabolism and Motivation (21:31)
Jean-Pierre Després, PhD
Cardiovascular Disease Under the Influence of Excess Visceral Fat (26:20)
Robert M. Anthenelli, MD
Cardiac Health and Nicotine Dependence: Achieving Smoking Cessation Through CB1 Receptor Blockade (22:17)
Luc Van Gaal, MD, PhD
Prospectus on Endocannabinoid Therapy: The Significance of the RIO Clinical Trial Program (31:14)
Moderator and Faculty
Panel Discussion and Program Summary/Conclusions (audio only) (23:00)

TEST INSTRUCTIONS

Please answer the 10 questions below, and then click the SUBMIT button. You must correctly answer at least 7 questions to pass; however, you may retake an incorrectly answered question as many times as you wish.

Feel free to refer to the course materials on the course navigation page both before and during this test. Please note that ALL the material on which the questions are based can be found in the slide presentations (without the audio).

Once you have passed the test, you will be directed to your personal CME account to complete the course survey (required by ACCME regulations) and to receive your electronic CME certificate (PDF file). We hope you find this online activity both educational and enjoyable, and thank you once again for participating.

  1. Which of the following conditions is not traditionally associated with the constellation of symptoms that characterizes metabolic syndrome?

    A. High LDL-C level
    B. Low HDL-C level
    C. High triglyceride levels
    D. Abdominal obesity
    E. Hypertension

  2. Which of the following approaches is recommended in the National Institutes of Health guide to the selection of therapies for obesity?

    A. Pharmacotherapy may be considered for overweight or obese patients, regardless of body mass index (BMI), given that rebound weight gain inevitably occurs in the vast majority of these patients if they fail to receive a pharmacologic agent.
    B. Pharmacotherapy should be administered to all overweight or obese patients who have comorbidities.
    C. Pharmacotherapy is appropriate only for patients whose comorbidities are metabolic rather than cardiovascular in nature, given that antiobesity agents may increase the heart rate.
    D. Diet, physical activity, and behavior therapy are the mainstays of obesity therapy for all classes of overweight or obese patients.
    E. Weight-loss surgery should be reserved for patients whose BMIs exceed 34.9 with or without the presence of comorbidities.

  3. What are the 2 most abundant endocannabinoids discovered to date?

    A. Anandamide and virodhamine
    B. Anandamide and 2-arachidonoylglycerol
    C. Anandamide and noladin
    D. 2-Arachidonoylglycerol and virodhamine
    E. Virodhamine and noladin

  4. Chronic overeating resulting in overstimulation of the endocannabinoid system affects which areas of the brain?

    A. Hippocampus and nucleus accumbens
    B. Hypothalamus and medulla oblongata
    C. Hippocampus and thalamus
    D. Thalamus and nucleus accumbens
    E. Hypothalamus and nucleus accumbens

  5. Nicotine modulates which neurotransmitter to create tobacco dependency?

    A. Dopamine
    B. Norepinephrine
    C. Serotonin
    D. Glutamate
    E. GABA

  6. Derived from adipose tissue, which endogenous substance demonstrates antidiabetic and cardioprotective properties?

    A. Leptin
    B. Ghrelin
    C. Adiponectin
    D. Cortisol
    E. Insulin

  7. Rimonabant, a CB1 antagonist, has been primarily studied against what other agent in a series of clinical trials enrolling overweight or obese patients?

    A. Orlistat
    B. Sibutramine
    C. Phentermine
    D. Dronabinol
    E. Placebo

  8. What was the most common comorbidity noted among the overweight or obese patients enrolled in the RIO-Europe clinical trial?

    A. Metabolic syndrome
    B. Dyslipidemia
    C. Hyperglycemia
    D. Hyperinsulinemia
    E. Hypertension

  9. What is the leading preventable cause of death worldwide?

    A. Microbial infections
    B. Obesity
    C. Motor vehicle accidents
    D. Smoking
    E. Firearms

  10. Results from a phase 2 smoking cessation trial comparing rimonabant with placebo showed what percentage of reduction in postcessation weight gain among quitters?

    A. 25%
    B. 40%
    C. 50%
    D. 60%
    E. 75%